Bring your innovation to the next level utilising our integrated services to support healthcare innovation companies and organisations.
Clinical Problem Statement – Formulation / Qualification
Having the right problem statement is crucial to any healthcare innovation. Having an over-engineered solution to the wrong problem statement is painful. Do speak to our clinicians early in your innovation Journey. (In addition, get a direct input From Key Opinion Leader / KOL)
Clinical Opinion - Innovation Iterations
Healthcare innovations typically go through a few iterations before a best in class solution is formed. Having KOL opinion on this iteration phase is important to give an innovation the greatest viability for market adoption.
Technology Landscaping / IP Positioning (Meta Analysis)
IP strategy and positioning is an important anchor-point for your innovation and we can help by advising you on ring-fencing your innovation as well as strategising the IP value of your innovation in comparison to the technology landscape your innovation plays in.
Clinical Strategy (Trial Design / Protocol)
We will help to match you to a Principal Investigator whom can lend strategic value in your clinical trial strategy
Test Bedding in Institution Setting NUHS / Alexandra Campus
Offering access to a full patient ward with 36 beds and a test bed site with 8 beds at Alexandra Hospital within the NUHS Cluster.
Digitised Test Bedding via ObvioHealth Proprietary Platform (Institution To Community)
Offers an effective and productive online way to test bed Class 1 and selective Class 2 devices from Hospital to Community/Home.
Path To Market / Market Entry Plan / Regulatory Advisory, Market Access And Path To Claims
Through our panel of clinical, industry and capital partners, we help you shape the clearest path to market. The team takes an extremely pragmatic view on path to market and hopes to support you in each step to the market.
Cost Benefit Analysis / Economic Modelling
In addition to clinical value proposition, sharpening your innovation with an economic value proposition adds strong value to your proposed healthcare solution.
Capital Needs - Investor Presentations and Fund Raising
We recognize the need for strategic capital to be there when you need it. With access to TKS1, a healthcare and life science focused venture fund, in partnership with Tikehau Capital, we are happy to facilitate pitching sessions to strategic capital partners.
Our Sponsors are here to help you chart the fastest and most realistic path to market
The National University Health System (NUHS) is an integrated Academic Health System and Regional Health System in Singapore that delivers value-driven, innovative and sustainable healthcare.
The headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.
SPRIM VENTURES invest in early stage health solutions leveraging the funnel of SPRIM’s sourcing, screening and selection processes.
SPRIM VENTURES benefits from SPRIM’s unique combination of skills and resources:
Strong and long established relationships with large healthcare companies. Global infrastructure of 19 offices around the world. Potential partnerships with more than 400 global customers.
Tikehau Capital and SPRIM Ventures have raised $50 million in its initial closing for their first venture capital fund TKS1, which will focus on early stage investments in med-tech and life science companies.
If you say yes to the following, go ahead and apply!
Are you a market-ready pre-Series A, early stage startup with valuation around 100-200K USD?
Are you based in or interested in entering Asia Pacific?
Are you comfortable with pitching in English?
Do you have a fantastic innovation prototype / product in healthcare?
Are you seeking Funds or Business opportunities with the region’s most active investors and medtech corporates?
Post your application, you will need to go through our panel for pitching, screening and discussion.
The 360° Engagement aimed at charting the most pragmatic approach to market entry/adoption. (PPP = Public Private Panel)
Prof Lawrence Ho
Prof Freddy Boey
SVP, Grad Ed &
Res Trans. NUS
Prof Lim Chwee Teck
Mr Richard Lim
Mr Chang Yew Kong
A/Prof Ngiam Kee Yuan
Dir. Surgical R&D
Dr. Michael Shleifer, PhD
Finance your business model and we hope in time you turn profitable.
Prog. Dir. Institute of
Health Innovation companies founded by Panel Members
Endomaster Pte Ltd
Endomaster produces a robotic-assisted surgical system for the removal of gastro-intestinal cancer through an endoscopic approach.
Endofotonics Pte Ltd
Endofotonics’ IMDX™ system is built on the Raman Spectroscopy technique – a vibrational technique capable of probing biomolecular changes associated with cellular transformation.
Clearbridge Accelerator is an incubator that focuses on Healthcare innovation such as precision medicine technology for disease treatment and prevention.
Clearbridge BioMedics Pte Ltd
Clearbridge BioMedics (CBB) specialises in novel platforms with applications in oncology research and diagnostics.
Flexosense Pte Ltd
FlexoSense is a spin-off from the National University of Singapore incorporated in 2016. The co-founders have experiences in startups, R&D, business development, sales & marketing, operations, and finance.
Amaranth Medical is dedicated to advancing the field of interventional cardiology through the development of the thinnest bioresorbable drug eluting scaffolds that perform like metallic stents.
Peregrine Ophthalmic Pte Ltd
Combining 50 years of experience in materials science and technology with our in-depth expertise of ophthalmology to develop proprietary drug delivery systems for the eye.
Robust Dynamics Pte Ltd
Robust Dynamics helps designers and manufacturers improve the physical robustness of products and components, particularly in the area of withstanding impacts and shocks.
MediLOT is a decentralised healthcare platform built on blockchain, Artificial Intelligence and database management system technologies for patients, healthcare providers, researchers and commercial companies.
Medical advancements are extending life spans. Big data will uncover a cure for cancer, nanotechnology will change drug delivery and targeted therapy, and three-dimensional (3D) printing will make prosthetics affordable and liberating. It is not hard to conceive that life expectancy may almost double to 150 years of age.
- Mark Barrenechea, OpenText CEO -